Phaseline

Targets › CD2

CD2 (T-cell surface antigen CD2): drug programs, companies and trials

3 programs from 3 companies in 7 trials: 5 Phase 1, 2 Phase 2; Oncology, Gastroenterology, Genitourinary; next expected readout May 2027.

CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function. (UniProt, P06729)

Open in Phaseline: the race on CD2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nefro Avillion Clinical DevelopmentSiplizumab
T-cell surface antigen CD2 inhibitor
CD2Phase 2Renal Transplant Failure and Rejection; Autoimmune Liver Disease; Renal Failure; Kidney FailureMar 2028
ITB-MedSiplizumab (TCD601)
T-cell surface antigen CD2 inhibitor
CD2Phase 2Liver TransplantationJun 2029
Memorial Sloan Kettering Cancer CenterAntithymocyte globulin (ATG)
Polyclonal antibody targeting T lymphocytes; immunosuppressant
CTLA4, CD2, CD3, CD4, CD8Phase 1Myeloid Diseases; Hematologic MalignanciesMay 2027

Conditions

Myeloid Diseases (1) Hematologic Malignancies (1) Renal Transplant Failure and Rejection (1) Autoimmune Liver Disease (1) Renal Failure (1) Kidney Failure (1) Liver Transplantation (1)

Modalities

mixed (2), small molecule (1)

Companies

Memorial Sloan Kettering Cancer Center (1) Nefro Avillion Clinical Development (1) ITB-Med (1)

Related targets

CTLA4 (1) CD3 (1) CD4 (1) CD8 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.